<p>在 2026 年 3 月，全球市場正面臨複雜的局面，受到中東地緣政治緊張局勢和波動的能源價格影響，主要指數表現不一。儘管大盤股面臨壓力，小盤和中盤指數如標普中盤 400 和羅素 2000 卻展現出韌性，為尋求未被發現的投資機會的投資者提供了潛在機會。在這樣的環境中，識別具有強大基本面的股票，以應對經濟不確定性，對於長期增長潛力至關重要。</p>
<h3>全球十大未被發現的強基本面股票</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>亞洲碼頭</td>
<td>25.82%</td>
<td>12.05%</td>
<td>17.00%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>VICOM</td>
<td>NA</td>
<td>9.48%</td>
<td>7.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saha-Union</td>
<td>1.08%</td>
<td>0.23%</td>
<td>18.09%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>自然食品國際控股</td>
<td>NA</td>
<td>8.04%</td>
<td>37.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>達芬國際控股</td>
<td>NA</td>
<td>19.20%</td>
<td>59.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ADDCN 科技</td>
<td>16.11%</td>
<td>8.80%</td>
<td>6.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palasino 控股</td>
<td>8.57%</td>
<td>4.07%</td>
<td>-18.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>風吟和控股</td>
<td>9.39%</td>
<td>53.36%</td>
<td>74.10%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Procimmo 集團</td>
<td>141.47%</td>
<td>6.84%</td>
<td>6.01%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>阿聯酋 GO 電信</td>
<td>NA</td>
<td>38.31%</td>
<td>54.97%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球未被發現的強基本面股票篩選器中的 3100 只股票的完整列表。</p>
<p>下面我們展示了一些通過我們篩選的股票。</p>
<h2>Aurisco 製藥有限公司 (SHSE:605116)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Aurisco 製藥有限公司專注於特殊複雜活性藥物成分（API）、藥物中間體和製劑的全球研究、開發、生產和銷售，市值為 108.5 億人民幣。</p>
<p><strong>運營：</strong> Aurisco 的收入主要來自複雜活性藥物成分（API）、藥物中間體和製劑的銷售。公司的市值為 108.5 億人民幣。</p>
<p>Aurisco 製藥作為製藥行業的小型企業，展現出強健的財務健康，負債權益比在五年內上升至 37.7%，但其利息支付由 EBIT 覆蓋 33 倍。公司擁有高質量的盈利，去年盈利增長達到 24.6%，超過行業平均水平的 8.1%。其市盈率為 28.1 倍，而中國市場的平均市盈率為 45.2 倍，顯示出良好的價值潛力。最近，Aurisco 完成了一項股票回購計劃，回購超過 200 萬股，金額為 6000 萬人民幣，截至今年 1 月初。</p>
<ul>
<li>通過我們的綜合健康報告深入瞭解 Aurisco 製藥有限公司的複雜情況。</li>
<li>通過訪問我們的歷史表現報告評估 Aurisco 製藥有限公司的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9343dee9-a005-457f-8e89-30f175b4b31c/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9343dee9-a005-457f-8e89-30f175b4b31c/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 3 月的 SHSE:605116 負債權益比</p>
<h2>青島新光束科技有限公司 (SHSE:688677)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 青島新光束科技有限公司專注於全球醫療內窺鏡儀器和光學產品的研究、開發、生產和銷售，市值為 56.7 億人民幣。</p>
<p><strong>運營：</strong> 青島新光束的收入主要來自內窺鏡和光學相關產品的銷售和維護，金額為 6.0261 億人民幣。公司的淨利潤率是評估其盈利能力的關鍵財務指標。</p>
<p>青島新光束科技作為科技領域的靈活參與者，展現出良好的前景，其市盈率為 37.8 倍，遠低於中國市場平均的 45.2 倍。公司在過去一年中實現了 26.8% 的強勁盈利增長，超過醫療設備行業 0.3% 的温和增長。銷售額從 4.4283 億人民幣上升至 6.0261 億人民幣，淨收入從 1.3535 億人民幣上升至 1.716 億人民幣，財務健康狀況良好；這進一步體現在負債權益比在五年內從 15.5% 降至 11.8%，以及最近的股票回購總額約為 5899 萬人民幣，反映出對未來前景的信心。</p>
<ul>
<li>解鎖我們對青島新光束科技有限公司股票分析的全面見解，查看此健康報告。</li>
<li>檢查青島新光束科技有限公司的歷史表現報告，以瞭解其過去的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3fe5c722-b1a8-447c-a4a4-aa4b8dea55e7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3fe5c722-b1a8-447c-a4a4-aa4b8dea55e7/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 3 月的 SHSE:688677 盈利和收入增長</p>
<h2>山東聖陽電源有限公司 (SZSE:002580)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 山東聖陽電源有限公司致力於全球綠色能源解決方案，市值約為 72.7 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要通過其工業部門（包括電池）產生收入，金額約為 33.6 億人民幣。</p>
<p>山東聖陽電源有限公司作為電氣行業的靈活參與者，展現出令人印象深刻的增長，去年盈利增長 15.8%，超過行業平均水平的 5.7%。公司的負債權益比在五年內略微上升，從 17.9% 上升至 19.2%，但其利息覆蓋率仍然強勁，達到 EBIT 的 30 倍，表明財務健康狀況良好。儘管其資本結構中存在一些槓桿擔憂，但憑藉高質量的盈利和 40.1 倍的市盈率低於中國市場平均的 45.2 倍，似乎在價值尋求者中處於良好位置。</p>
<ul>
<li>點擊這裏瞭解山東聖陽電源有限公司的細微差別，查看我們的詳細分析健康報告。</li>
<li>通過查看我們的歷史報告，瞭解山東聖陽電源有限公司的業績記錄。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4281ccc6-9a0d-406b-8286-f95eb7e24479/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4281ccc6-9a0d-406b-8286-f95eb7e24479/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:002580 截至 2026 年 3 月的收益和收入增長</p>
<h2>抓住機會</h2>
<ul>
<li>點擊這裏更深入地查看我們 3100 傢俱有強大基本面的全球未被發現的優質公司名單。</li>
<li>在這些股票中有投資嗎？通過使用 Simply Wall St 的投資組合提升您的管理方式，直觀的工具將幫助您優化投資結果。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受免費訪問涵蓋每個大洲的市場情報。</li>
</ul>
<h2>對其他選項感興趣？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
<p>我們為股票投資者創建了 <strong>終極投資組合助手</strong>，<strong>而且是免費的。</strong></p>
<p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
<p>• 通過電子郵件或手機接收新的警告信號或風險提醒</p>
<p>• 跟蹤您股票的公允價值</p>
<p>免費試用演示投資組合</p>

美國小盤價值股 ETF - Avantis

羅素 2000 價值股指數 ETF - iShares

IWMI

<p>在 2026 年 3 月，全球市場因地緣政治緊張局勢和波動的能源價格而表現不一。雖然大盤股面臨壓力，但小盤和中盤指數如標普 400 中盤股和羅素 2000 展現出韌性，為投資者提供了機會。一份包含強大基本面的前 10 大未被發現的潛力股名單中，包括了 Aurisco Pharmaceutical、青島新光束科技和山東聖陽電源等公司，這些公司都展現出強健的財務健康和增長潛力。投資者被鼓勵在經濟不確定性中探索這些股票，以實現長期增長</p>

<p>In March 2026, global markets have been navigating a complex landscape marked by geopolitical tensions in the Middle East and fluctuating energy prices, leading to mixed performances across key indices. While large-cap stocks face pressure, small- and mid-cap indexes like the S&amp;P MidCap 400 and Russell 2000 have shown resilience, highlighting potential opportunities for investors seeking undiscovered gems. In such an environment, identifying stocks with strong fundamentals that can withstand economic uncertainties becomes crucial for long-term growth potential.</p>
<div class="lb-trans"><p>在 2026 年 3 月，全球市場正面臨複雜的局面，受到中東地緣政治緊張局勢和波動的能源價格影響，主要指數表現不一。儘管大盤股面臨壓力，小盤和中盤指數如標普中盤 400 和羅素 2000 卻展現出韌性，為尋求未被發現的投資機會的投資者提供了潛在機會。在這樣的環境中，識別具有強大基本面的股票，以應對經濟不確定性，對於長期增長潛力至關重要。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals Globally</h3>
<div class="lb-trans"><h3>全球十大未被發現的強基本面股票</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asian Terminals</td>
<td>25.82%</td>
<td>12.05%</td>
<td>17.00%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>VICOM</td>
<td>NA</td>
<td>9.48%</td>
<td>7.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saha-Union</td>
<td>1.08%</td>
<td>0.23%</td>
<td>18.09%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Natural Food International Holding</td>
<td>NA</td>
<td>8.04%</td>
<td>37.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Daphne International Holdings</td>
<td>NA</td>
<td>19.20%</td>
<td>59.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ADDCN Technology</td>
<td>16.11%</td>
<td>8.80%</td>
<td>6.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palasino Holdings</td>
<td>8.57%</td>
<td>4.07%</td>
<td>-18.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Fengyinhe Holdings</td>
<td>9.39%</td>
<td>53.36%</td>
<td>74.10%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Procimmo Group</td>
<td>141.47%</td>
<td>6.84%</td>
<td>6.01%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Etihad GO Telecom</td>
<td>NA</td>
<td>38.31%</td>
<td>54.97%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>亞洲碼頭</td>
<td>25.82%</td>
<td>12.05%</td>
<td>17.00%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>VICOM</td>
<td>NA</td>
<td>9.48%</td>
<td>7.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saha-Union</td>
<td>1.08%</td>
<td>0.23%</td>
<td>18.09%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>自然食品國際控股</td>
<td>NA</td>
<td>8.04%</td>
<td>37.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>達芬國際控股</td>
<td>NA</td>
<td>19.20%</td>
<td>59.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ADDCN 科技</td>
<td>16.11%</td>
<td>8.80%</td>
<td>6.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palasino 控股</td>
<td>8.57%</td>
<td>4.07%</td>
<td>-18.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>風吟和控股</td>
<td>9.39%</td>
<td>53.36%</td>
<td>74.10%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Procimmo 集團</td>
<td>141.47%</td>
<td>6.84%</td>
<td>6.01%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>阿聯酋 GO 電信</td>
<td>NA</td>
<td>38.31%</td>
<td>54.97%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 3100 stocks from our Global Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球未被發現的強基本面股票篩選器中的 3100 只股票的完整列表。</p>
</div><p>Underneath we present a selection of stocks filtered out by our screen.</p>
<div class="lb-trans"><p>下面我們展示了一些通過我們篩選的股票。</p>
</div><h2>Aurisco PharmaceuticalLtd (SHSE:605116)</h2>
<div class="lb-trans"><h2>Aurisco 製藥有限公司 (SHSE:605116)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Aurisco Pharmaceutical Co., Ltd. is involved in the global research, development, production, and sales of special complex active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and preparations, with a market capitalization of CN¥10.85 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aurisco 製藥有限公司專注於特殊複雜活性藥物成分（API）、藥物中間體和製劑的全球研究、開發、生產和銷售，市值為 108.5 億人民幣。</p>
</div><p><strong>Operations:</strong> Aurisco generates revenue primarily from the sale of complex active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and preparations. The company's market capitalization is CN¥10.85 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> Aurisco 的收入主要來自複雜活性藥物成分（API）、藥物中間體和製劑的銷售。公司的市值為 108.5 億人民幣。</p>
</div><p>Aurisco Pharmaceutical, a small cap player in the pharma sector, has shown robust financial health with a debt to equity ratio climbing to 37.7% over five years, yet its interest payments are comfortably covered 33 times by EBIT. The company boasts high-quality earnings and an impressive earnings growth of 24.6% last year, outpacing the industry average of 8.1%. Its price-to-earnings ratio stands at 28.1x compared to the broader CN market's 45.2x, suggesting good value potential. Recently, Aurisco completed a share buyback program repurchasing over 2 million shares for CNY 60 million as of early January this year.</p>
<div class="lb-trans"><p>Aurisco 製藥作為製藥行業的小型企業，展現出強健的財務健康，負債權益比在五年內上升至 37.7%，但其利息支付由 EBIT 覆蓋 33 倍。公司擁有高質量的盈利，去年盈利增長達到 24.6%，超過行業平均水平的 8.1%。其市盈率為 28.1 倍，而中國市場的平均市盈率為 45.2 倍，顯示出良好的價值潛力。最近，Aurisco 完成了一項股票回購計劃，回購超過 200 萬股，金額為 6000 萬人民幣，截至今年 1 月初。</p>
</div><ul>
<li>Navigate through the intricacies of Aurisco PharmaceuticalLtd with our comprehensive health report here.</li>
<li>Evaluate Aurisco PharmaceuticalLtd's historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的綜合健康報告深入瞭解 Aurisco 製藥有限公司的複雜情況。</li>
<li>通過訪問我們的歷史表現報告評估 Aurisco 製藥有限公司的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9343dee9-a005-457f-8e89-30f175b4b31c/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/9343dee9-a005-457f-8e89-30f175b4b31c/chart/debt-equity-history-analysis"/></p>
<p>SHSE:605116 Debt to Equity as at Mar 2026</p>
<div class="lb-trans"><p>截至 2026 年 3 月的 SHSE:605116 負債權益比</p>
</div><h2>Qingdao NovelBeam TechnologyLtd (SHSE:688677)</h2>
<div class="lb-trans"><h2>青島新光束科技有限公司 (SHSE:688677)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Qingdao NovelBeam Technology Co., Ltd. specializes in the research, development, production, and sales of medical endoscopic instruments and optical products globally, with a market cap of CN¥5.67 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 青島新光束科技有限公司專注於全球醫療內窺鏡儀器和光學產品的研究、開發、生產和銷售，市值為 56.7 億人民幣。</p>
</div><p><strong>Operations:</strong> Qingdao NovelBeam derives its revenue primarily from the sales and maintenance of endoscopes and optical-related products, amounting to CN¥602.61 million. The company's net profit margin is a key financial metric to consider when evaluating its profitability.</p>
<div class="lb-trans"><p><strong>運營：</strong> 青島新光束的收入主要來自內窺鏡和光學相關產品的銷售和維護，金額為 6.0261 億人民幣。公司的淨利潤率是評估其盈利能力的關鍵財務指標。</p>
</div><p>Qingdao NovelBeam Technology, a nimble player in the tech space, is showing promising signs with its price-to-earnings ratio at 37.8x, well below the CN market average of 45.2x. The company has demonstrated robust earnings growth of 26.8% over the past year, outpacing the medical equipment industry’s modest increase of 0.3%. With sales climbing to CNY 602.61 million from CNY 442.83 million and net income rising to CNY 171.6 million from CNY 135.35 million year-on-year, its financial health appears strong; this is further underscored by a debt-to-equity ratio reduction from 15.5% to 11.8% over five years and recent share buybacks totaling approximately CNY 58.99 million for about a combined total of around1 .33%, reflecting confidence in future prospects.</p>
<div class="lb-trans"><p>青島新光束科技作為科技領域的靈活參與者，展現出良好的前景，其市盈率為 37.8 倍，遠低於中國市場平均的 45.2 倍。公司在過去一年中實現了 26.8% 的強勁盈利增長，超過醫療設備行業 0.3% 的温和增長。銷售額從 4.4283 億人民幣上升至 6.0261 億人民幣，淨收入從 1.3535 億人民幣上升至 1.716 億人民幣，財務健康狀況良好；這進一步體現在負債權益比在五年內從 15.5% 降至 11.8%，以及最近的股票回購總額約為 5899 萬人民幣，反映出對未來前景的信心。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Qingdao NovelBeam TechnologyLtd stock in this health report.</li>
<li>Examine Qingdao NovelBeam TechnologyLtd's past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對青島新光束科技有限公司股票分析的全面見解，查看此健康報告。</li>
<li>檢查青島新光束科技有限公司的歷史表現報告，以瞭解其過去的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3fe5c722-b1a8-447c-a4a4-aa4b8dea55e7/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/3fe5c722-b1a8-447c-a4a4-aa4b8dea55e7/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688677 Earnings and Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>截至 2026 年 3 月的 SHSE:688677 盈利和收入增長</p>
</div><h2>Shandong Sacred Sun Power SourcesLtd (SZSE:002580)</h2>
<div class="lb-trans"><h2>山東聖陽電源有限公司 (SZSE:002580)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Shandong Sacred Sun Power Sources Co., Ltd is engaged in providing green energy solutions globally and has a market capitalization of approximately CN¥7.27 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 山東聖陽電源有限公司致力於全球綠色能源解決方案，市值約為 72.7 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its industrial segment, including batteries, amounting to approximately CN¥3.36 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其工業部門（包括電池）產生收入，金額約為 33.6 億人民幣。</p>
</div><p>Shandong Sacred Sun Power Sources Ltd., a nimble player in the electrical industry, has shown impressive growth with earnings rising 15.8% last year, outpacing the industry average of 5.7%. The company's debt-to-equity ratio slightly increased over five years from 17.9% to 19.2%, yet its interest coverage remains robust at 30 times EBIT, indicating strong financial health. With high-quality earnings and a price-to-earnings ratio of 40.1x below the China market average of 45.2x, it seems well-positioned for value seekers despite some leverage concerns in its capital structure.</p>
<div class="lb-trans"><p>山東聖陽電源有限公司作為電氣行業的靈活參與者，展現出令人印象深刻的增長，去年盈利增長 15.8%，超過行業平均水平的 5.7%。公司的負債權益比在五年內略微上升，從 17.9% 上升至 19.2%，但其利息覆蓋率仍然強勁，達到 EBIT 的 30 倍，表明財務健康狀況良好。儘管其資本結構中存在一些槓桿擔憂，但憑藉高質量的盈利和 40.1 倍的市盈率低於中國市場平均的 45.2 倍，似乎在價值尋求者中處於良好位置。</p>
</div><ul>
<li>Click here to discover the nuances of Shandong Sacred Sun Power SourcesLtd with our detailed analytical health report.</li>
<li>Understand Shandong Sacred Sun Power SourcesLtd's track record by examining our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解山東聖陽電源有限公司的細微差別，查看我們的詳細分析健康報告。</li>
<li>通過查看我們的歷史報告，瞭解山東聖陽電源有限公司的業績記錄。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4281ccc6-9a0d-406b-8286-f95eb7e24479/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/4281ccc6-9a0d-406b-8286-f95eb7e24479/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:002580 Earnings and Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>SZSE:002580 截至 2026 年 3 月的收益和收入增長</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Take a closer look at our Global Undiscovered Gems With Strong Fundamentals list of 3100 companies by clicking here.</li>
<li>Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏更深入地查看我們 3100 傢俱有強大基本面的全球未被發現的優質公司名單。</li>
<li>在這些股票中有投資嗎？通過使用 Simply Wall St 的投資組合提升您的管理方式，直觀的工具將幫助您優化投資結果。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受免費訪問涵蓋每個大洲的市場情報。</li>
</ul>
</div><h2>Curious About Other Options?</h2>
<div class="lb-trans"><h2>對其他選項感興趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我們為股票投資者創建了 <strong>終極投資組合助手</strong>，<strong>而且是免費的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通過電子郵件或手機接收新的警告信號或風險提醒</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟蹤您股票的公允價值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免費試用演示投資組合</p>
</div>

Undiscovered Gems in Global Markets for March 2026

- 全球市場受地緣局勢及能源價格波動影響，主要指數表現各異。  
- 大型股面臨壓力，中小型股如 S&P MidCap 400 展現韌性，投資機會顯現。  
- 尋找財務健康、能抗經濟不確定性的股票對長期增長潛力至關重要。

2026 年 3 月全球市場中的未被髮掘的潛力股